Cancer Therapeutics Response Portal

CTRP Portal Version 2
The CTRP portal vesion 2 is now available.
Go there now
Don't show this again: stay on version 1
CTRP Portal Outage
The CTRP portal will be unavailable from Thursday October 17 through Sunday October 20th for server maintenance.
Don't show this again: Close

Profiling cancer cell-line sensitivities with small molecules

an NCI CTD2 Network project

Several protein kinase-targeting drugs are yielding high clinical response rates when matched to cancer patients with specific genomic alterations in their cancers. Several other cancer drugs yield similarly high response rates within a particular cancer lineage. These clinical successes have prompted our efforts to identify more systematically additional genetic and lineage context-dependent small-molecule sensitivities.

We have generated a novel ‘Informer Set’ of small-molecule probes and drugs that each selectively target a distinct node in cell circuitry and that collectively modulate a broad array of cell processes. By profiling the impact of this small-molecule collection on a panel of cancer cell lines for which extensive genetic characterizations are publicly available, we have generated a dataset that can be used to identify comprehensively relationships between genetic and lineage features of human cancer cell lines and small-molecule sensitivities.

Publications

Please cite our cancer cell-line profiling Resource by referencing:
"An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules" Basu, Bodycombe, Cheah, et al., Cell, 154, 1151-1161 (2013). Supporting Information accompanying the Resource paper contains all raw sensitivity and enrichment data.

New Development

News goes here

Acknowledgements

The Cancer Therapeutics Response Portal was developed by researchers at the Center for the Science of Therapeutics at the Broad Institute and is sponsored in part by the NCI's Cancer Target Discovery and Development Network.

Complementary Resources

The National Cancer Institute’s CTD2 Network maintains an Open-Access Data Matrix that makes available raw data downloads from member Centers, including all raw sensitivity and enrichment data and other supporting information from the Broad related to this portal.

The Cancer Cell Line Encyclopedia provides public access to genomic data, analysis and visualization for about 1000 cell lines.

The Genomics of Drug Sensitivity in Cancer provides public access to data on the sensitivity of genomically characterized cancer cell lines to select compounds.

Project Achilles is a systematic effort aimed at identifying and cataloging genetic vulnerabilities across hundreds of genomically characterized cancer cell lines.


The Cancer Therapeutics Response Portal provides open access to the results obtained through quantitatively measuring the sensitivity of 242 genetically characterized cancer-cell lines to a 354-member ‘Informer Set’ of small-molecule probes and drugs. Statistically significant correlations identified between the genetic and lineage features of the cell lines and small-molecule sensitivities are accessible through the portal. With this dataset, users can mine for genetic correlations in a lineage-specific context and control for potential confounding factors. We anticipate continuing to expand the dataset in the portal, providing a living resource for the cancer-research community. We hope that the Portal can be used to develop novel therapeutic hypotheses and to accelerate future discovery of drugs matched to patients based on their cancer genotype and lineage.



The CTRP currently lists 76,703 connections to 185 compounds at a false-discovery rate q-value cutoff of q<0.01.